165 related articles for article (PubMed ID: 15007951)
1. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
[No Abstract] [Full Text] [Related]
2. [IL-6 targetting therapy for inflammatory immune diseases].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1795-800. PubMed ID: 17037317
[No Abstract] [Full Text] [Related]
3. Technology evaluation: MRA, Chugai.
Ding C; Jones G
Curr Opin Mol Ther; 2003 Feb; 5(1):64-9. PubMed ID: 12669473
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
5. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
Nishimoto N; Kishimoto T; Yoshizaki K
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
[TBL] [Abstract][Full Text] [Related]
6. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.
Chen YH; Shiao RT; Labayog JM; Modi S; Lavelle D
Leuk Lymphoma; 1997 Sep; 27(1-2):11-23. PubMed ID: 9373192
[TBL] [Abstract][Full Text] [Related]
7. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
8. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
Beck JT; Hsu SM; Wijdenes J; Bataille R; Klein B; Vesole D; Hayden K; Jagannath S; Barlogie B
N Engl J Med; 1994 Mar; 330(9):602-5. PubMed ID: 8302342
[No Abstract] [Full Text] [Related]
9. The blockade of IL-6 signaling in rational drug design.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
Yoshio-Hoshino N; Adachi Y; Aoki C; Pereboev A; Curiel DT; Nishimoto N
Cancer Res; 2007 Feb; 67(3):871-5. PubMed ID: 17283116
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
12. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
Nishimoto N
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of IL6 inhibitors.
Klein B; Lu ZY; Bataille R
Res Immunol; 1992 Sep; 143(7):774-6. PubMed ID: 1439155
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Montero-Julian FA; Gautherot E; Wijdenes J; Klein B; Brailly H
J Interferon Res; 1994 Oct; 14(5):301-2. PubMed ID: 7861038
[No Abstract] [Full Text] [Related]
15. [Anti-IL-6 receptor antibody].
Nishimoto N
Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
[No Abstract] [Full Text] [Related]
16. [MRA for therapy of rheumatoid arthritis].
Nishimoto N; Mihara M
Nihon Rinsho; 2005 Jan; 63 Suppl 1():538-43. PubMed ID: 15799414
[No Abstract] [Full Text] [Related]
17. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
18. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
19. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
Nishimoto N
Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6, a new target for therapy in multiple myeloma?
van Oers MH; van Zaanen HC; Lokhorst HM
Ann Hematol; 1993 May; 66(5):219-23. PubMed ID: 8507716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
